Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791330369> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2791330369 abstract "Background: Although treatment of eribulin mesylate (E) improved overall survival in metastatic breast cancer (BC) patients, little is known about the efficacy in early BC. The hypothesis of this study is that sequential administration of E followed by FEC would have less toxic, particularly peripheral neuropathy, and also have similar effect compared to paclitaxel (P) followed by FEC as primary systemic therapy (PST) for woman with operable BC. Methods: This is a phase II multicenter open label study (UMI12817). Patients (pts) were randomly assigned to either E (1.4mg/m2, d1 and d8, q21 days, 4 cycles) + FEC (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2) or P (80mg/m2, weekly, 12 cycles) + FEC as PST. HER2+ patients were allowed to receive trastuzumab. Stratification factors were ER, HER2, and menopausal status. Primary endpoint was the incidence of peripheral sensory and motor neuropathy (PSN and PMN) with Grade 1 or higher according to CTCAE ver.4.0. Secondary endpoints were pathological complete response (pCR) rates (ypT0/is/ypN0), clinical response rates (CR+PR), and adverse events. Safety was assessed in all pts who received at least one dose of the study drug. Results: Between 12/2013 to 3/2016, 121 pts were randomly assigned equally to E + FEC and P + FEC. Excluding 5 pts from the primary assessment, 116 pts (58 in each group) were included in the full analysis set. The characteristics of the pts were similar in the two arms. At the end of E or P administration, the incidences of PSN were 55.4% and 92.9% in E and P arm, respectively (p Conclusion: This randomized phase II study revealed that eribulin had favorable peripheral neuropathy profile with modest efficacy in the neoadjuvant setting, compared with paclitaxel. Citation Format: Miura D, Hasegawa Y, Ishikawa T, Tachibana A, Horiguchi J, Hayashi M, Miyashita M, Kubota T, Narui K, Suzuki M, Akazawa K, Kohno N. Randomized controlled trial of neoadjuvant eribulin mesylate versus paclitaxel in women with operable breast cancer (JONIE-3 study) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-15-05." @default.
- W2791330369 created "2018-03-29" @default.
- W2791330369 creator A5002514266 @default.
- W2791330369 creator A5007274064 @default.
- W2791330369 creator A5015062076 @default.
- W2791330369 creator A5015156741 @default.
- W2791330369 creator A5027590719 @default.
- W2791330369 creator A5028664306 @default.
- W2791330369 creator A5033593063 @default.
- W2791330369 creator A5035036689 @default.
- W2791330369 creator A5044077496 @default.
- W2791330369 creator A5062104407 @default.
- W2791330369 creator A5067950730 @default.
- W2791330369 creator A5072087774 @default.
- W2791330369 date "2018-02-14" @default.
- W2791330369 modified "2023-09-26" @default.
- W2791330369 title "Abstract P6-15-05: Randomized controlled trial of neoadjuvant eribulin mesylate versus paclitaxel in women with operable breast cancer (JONIE-3 study)" @default.
- W2791330369 doi "https://doi.org/10.1158/1538-7445.sabcs17-p6-15-05" @default.
- W2791330369 hasPublicationYear "2018" @default.
- W2791330369 type Work @default.
- W2791330369 sameAs 2791330369 @default.
- W2791330369 citedByCount "0" @default.
- W2791330369 crossrefType "proceedings-article" @default.
- W2791330369 hasAuthorship W2791330369A5002514266 @default.
- W2791330369 hasAuthorship W2791330369A5007274064 @default.
- W2791330369 hasAuthorship W2791330369A5015062076 @default.
- W2791330369 hasAuthorship W2791330369A5015156741 @default.
- W2791330369 hasAuthorship W2791330369A5027590719 @default.
- W2791330369 hasAuthorship W2791330369A5028664306 @default.
- W2791330369 hasAuthorship W2791330369A5033593063 @default.
- W2791330369 hasAuthorship W2791330369A5035036689 @default.
- W2791330369 hasAuthorship W2791330369A5044077496 @default.
- W2791330369 hasAuthorship W2791330369A5062104407 @default.
- W2791330369 hasAuthorship W2791330369A5067950730 @default.
- W2791330369 hasAuthorship W2791330369A5072087774 @default.
- W2791330369 hasConcept C121608353 @default.
- W2791330369 hasConcept C126322002 @default.
- W2791330369 hasConcept C141071460 @default.
- W2791330369 hasConcept C143998085 @default.
- W2791330369 hasConcept C168563851 @default.
- W2791330369 hasConcept C197934379 @default.
- W2791330369 hasConcept C203092338 @default.
- W2791330369 hasConcept C2780835546 @default.
- W2791330369 hasConcept C530470458 @default.
- W2791330369 hasConcept C71924100 @default.
- W2791330369 hasConcept C90924648 @default.
- W2791330369 hasConceptScore W2791330369C121608353 @default.
- W2791330369 hasConceptScore W2791330369C126322002 @default.
- W2791330369 hasConceptScore W2791330369C141071460 @default.
- W2791330369 hasConceptScore W2791330369C143998085 @default.
- W2791330369 hasConceptScore W2791330369C168563851 @default.
- W2791330369 hasConceptScore W2791330369C197934379 @default.
- W2791330369 hasConceptScore W2791330369C203092338 @default.
- W2791330369 hasConceptScore W2791330369C2780835546 @default.
- W2791330369 hasConceptScore W2791330369C530470458 @default.
- W2791330369 hasConceptScore W2791330369C71924100 @default.
- W2791330369 hasConceptScore W2791330369C90924648 @default.
- W2791330369 hasLocation W27913303691 @default.
- W2791330369 hasOpenAccess W2791330369 @default.
- W2791330369 hasPrimaryLocation W27913303691 @default.
- W2791330369 hasRelatedWork W1569344663 @default.
- W2791330369 hasRelatedWork W1712386042 @default.
- W2791330369 hasRelatedWork W1876716199 @default.
- W2791330369 hasRelatedWork W2000651446 @default.
- W2791330369 hasRelatedWork W2087003997 @default.
- W2791330369 hasRelatedWork W2110804158 @default.
- W2791330369 hasRelatedWork W2234057311 @default.
- W2791330369 hasRelatedWork W2338788500 @default.
- W2791330369 hasRelatedWork W2344442798 @default.
- W2791330369 hasRelatedWork W2394493995 @default.
- W2791330369 hasRelatedWork W2408422038 @default.
- W2791330369 hasRelatedWork W2503852651 @default.
- W2791330369 hasRelatedWork W2560286399 @default.
- W2791330369 hasRelatedWork W2593203381 @default.
- W2791330369 hasRelatedWork W2792182565 @default.
- W2791330369 hasRelatedWork W2919093067 @default.
- W2791330369 hasRelatedWork W2944498830 @default.
- W2791330369 hasRelatedWork W3009101260 @default.
- W2791330369 hasRelatedWork W3129208430 @default.
- W2791330369 hasRelatedWork W76445704 @default.
- W2791330369 isParatext "false" @default.
- W2791330369 isRetracted "false" @default.
- W2791330369 magId "2791330369" @default.
- W2791330369 workType "article" @default.